Free website hits

Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of blue skies and mild temperatures hovering about the Pharmalot campus. To celebrate, yes, we are brewing cups of stimulation again. Our choice today is cinnamon mocha. Feel free to join us or grab a bottle of water, if you prefer. Meanwhile, here is the usual menu of tidbits to start your journey. We hope all goes well today and that you conquer the world. As always, we encourage you to keep in touch and, of course, stay safe — wear a mask. …

A World Health Organization-led effort to supply Covid-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but an internal document shows the agency is shunning the Gilead Sciences (GILD) drug remdesivir, Reuters reports. The draft document says the priorities are to secure monoclonal antibodies in a tight market and to boost purchases and distribution of the cheap steroid dexamethasone, of which it has already booked nearly 3 million courses of treatment for poorer countries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]